3 cases of distantly metastatic BCC have been reported in the literature in patients with Gorlin syndrome. [5] [6] [7] The BCCs in patients with Gorlin syndrome have been reported to have sensitivity to targeted therapy against the SMO protein, the downstream effector of PTCH1. 8 Although it is known that locally advanced BCCs in patients with Gorlin syndrome can be refractory to (primary resistance) or regrow (secondary resistance) after Smoothened (SMO) inhibitors, 9 neither primary nor secondary resistance has been described in distantly metastatic BCCs in this high-risk population.
We report a case of Gorlin syndrome in a patient with biopsy-proven metastatic BCC to the lung that was refractory to 2 different SMO inhibitors despite responses in his cutaneous BCCs. Because this is a single case report, no institutional review board approval was required. The patient provided written consent to have his case reported.
Report of a Case
A man in his 50s with Gorlin syndrome presented with innumerable BCCs on his head, neck, trunk, and 4 extremities. The largest BCC had been present for 18 months and was a locally advanced, ulcerated, left postauricular lesion (6.4 × 6.0 cm) that encased the facial nerve. The area of the locally advanced BCC had been exposed to radiation therapy 20 years earlier to treat other BCCs in that region. The lesion had continued to grow despite topical treatments with fluorouracil and nitrogen mustard. Computed tomography (CT) revealed that the underlying bone was not involved with the tumor. However, the patient reported that his surgeons had recommended against excision because of the extent of his disease and the risk of facial nerve damage and hearing loss.
The patient's medical history was significant for stage 2 testicular cancer, diagnosed 10 years earlier, which was successfully treated with bleomycin sulfate, etoposide, and cisplatin. During this treatment, the patient noted incidental shrinkage of all his BCCs. However, this combination chemotherapy left him with persistent shortness of breath, neuropathy, and chronic renal compromise.
The patient's metastatic BCC was first discovered 16 months earlier when he presented to his local emergency department for chest pain. As part of his evaluation, he underwent chest CT, IMPORTANCE Basal cell carcinomas (BCCs) in patients with Gorlin syndrome have been reported to be extremely sensitive to Smoothened (SMO) inhibitors, a novel targeted therapy against the Hedgehog pathway, because of characteristic mutations in these patients. A few cases of disease refractory to oral therapy with SMO inhibitors have been reported in patients with Gorlin syndrome and nonmetastatic BCCs, but refractory disease in distantly metastatic tumors has not been documented in this high-risk group.
OBSERVATIONS A man with Gorlin syndrome and innumerable cutaneous BCCs presented with biopsy-proven BCC in his lungs. After SMO inhibitor therapy, almost all of his cutaneous tumors shrank, but his lung metastases did not. These lung metastases remained refractory to treatment despite institution of a second SMO inhibitor.
CONCLUSIONS AND RELEVANCE
We report a case of Gorlin syndrome in a patient with metastatic BCC refractory to SMO inhibitors. Furthermore, clinical responses in this patient's cutaneous tumors did not parallel the responses in the distant site. However, serial imaging after diagnosis of metastatic disease can be critical to monitor for response to therapy.
gib. However, his metastatic BCCs remained stable in size on CT scans, indicating refractory disease. Sixteen months after initiating saridegib therapy, a new 1.1-cm, right, apical lung nodule was discovered on a CT scan, and he was discontinued from the study because of disease progression.
Because of his comorbidities and lack of treatment options, the patient enrolled in a second clinical study (NCT01160250) using a different SMO inhibitor, vismodegib, after a protocolmandated 1-month washout from saridegib. He received 150 mg/ d, and his cutaneous lesions continued to shrink on this regimen. However, after 4 months of vismodegib treatment, his lung CT scan revealed enlargement of his preexisting pulmonary nodules and the appearance of new nodules (Figure 2) .
After discussion with his medical oncologist and presentation at a multidisciplinary head and neck tumor board, the consensus was that the new nodules were likely metastatic BCC and an additional biopsy of the lung was not needed. The patient was discontinued from the study because of disease progression but continued to receive vismodegib as part of his dermatology care to control his numerous cutaneous BCCs. The patient is currently considering other clinical trials for his refractory metastatic BCCs.
Discussion
This case illustrates 4 clinical teaching points. First, patients with Gorlin syndrome can develop distantly metastatic BCCs. Only 3 cases of distant metastatic BCCs have been reported in patients with Gorlin syndrome, suggesting either the rarity of this phenomenon or detection bias because of a lack of surveillance by health care professionals. [5] [6] [7] The prevalence of metastatic BCCs in patients with Gorlin syndrome compared with patients with sporadic BCCs is not known. Second, this case highlights the importance of tissue biopsy after a positive finding on imaging to confirm the diagnosis of BCC at a distant site. The patient's history of testicular cancer put a testicular cancer metastasis in the differential diagnosis for the lung nodules. In older patients, more common cancers, such as colon or breast cancer metastases, should be considered as well. The scans reveal growth of existing basal cell carcinomas (A) and development of new nodules (B, arrow) in the left apical lung while undergoing Smoothened inhibition therapy.
